Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00404066
Status:
COMPLETED
Last Update Posted:
2017-12-22
First Post:
2006-11-22
Brief Title:
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide - Docetaxel With Lapatinib in Stage IIIII Her2Neu Breast Cancer
Sponsor:
George Albert Fisher
Organization:
Stanford University
Organization Data
Organization:
Stanford University
Class:
OTHER
Study ID:
IRB-03518
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
George Albert Fisher
Lead Sponsor Class:
OTHER
Responsible Party:
George Albert Fisher
Responsible Party Title:
Associate Professor of Medicine
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Stanford University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
| GlaxoSmithKline | INDUSTRY |